Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Beijing Kanova Biopharmaceutical Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution is handled by a distinct examiner and 1 distinct art unit, representing a highly concentrated examination profile. CESARE, JOSEPH DAVID is identified as the busiest examiner for the portfolio, currently reviewing the pending matter.
The concentration of the portfolio under a single examiner and art unit suggests a focused prosecution strategy. For a practitioner, this environment means that all current USPTO feedback originates from a single source, allowing for a consistent response strategy. The technical arguments presented in the pending action do not need to be reconciled with conflicting feedback from other art units or examiners. This centralization is a defining feature of the company's current interaction with the patent office.
In the Biotechnology & Pharmaceuticals sector, maintaining a unified prosecution record is often critical for long-term portfolio value. Since the company is only dealing with a distinct examiner, the risk of inconsistent claim interpretations is minimized. This centralized review process allows the applicant to focus resources on the specific requirements and examination style of the assigned official, ensuring a more predictable path toward allowance for the pending application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CESARE, JOSEPH DAVID | 1 | — | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18562298 | ANTI-PD-1 POLYPEPTIDES AND THEIR USE | CESARE, JOSEPH DAVID | 1618 | §112 | Non-Final OA | — | Pending | Nov 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBeijing Kanova Biopharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Joseph David Cesare has the most, with 1 of Beijing Kanova Biopharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
